PrimaryLogo_Mango-05.png
MangoRx Introduces Oral Tirzepatide GLP-1 Receptor Agonist for Advanced Weight Loss Solutions
October 03, 2024 08:30 ET | Mangoceuticals, Inc.
Dallas, Texas, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling men’s health and wellness...
PrimaryLogo_Mango-05.png
MangoRx Reports 1,685% Increase in Shareholders’ Equity From December 31, 2023, to $13.8MM, and 56% Increase in Year-Over-Year Revenue for First Half of 2024
August 15, 2024 09:25 ET | Mangoceuticals, Inc.
Dallas, Texas, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health...
PrimaryLogo_Mango-05.png
Mangoceuticals CEO Jacob Cohen Featured on Benzinga All-Access
July 18, 2024 16:05 ET | Mangoceuticals, Inc.
DALLAS, TEXAS, July 18, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("MangoRx" or the "Company”), a company focused on developing, marketing, and selling a variety of men’s health...
PrimaryLogo_Mango-05.png
MangoRx Secures DEA Approval for Proprietary HIPAA-Compliant Operating System via Surescripts
July 16, 2024 08:20 ET | Mangoceuticals, Inc.
DALLAS, TX, July 16, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and...
PrimaryLogo_Mango-05.png
MangoRx Announces Strategic Partnership for Expansion into Asia Pacific and Key Emerging Markets
July 11, 2024 08:15 ET | Mangoceuticals, Inc.
DALLAS, TEXAS, July 11, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men’s health...
PrimaryLogo_Mango-05.png
MangoRx Receives Notice of Acceptance for Patent Application in Australia for Respiratory Illness and Preventive Care Technology
June 06, 2024 08:30 ET | Mangoceuticals, Inc.
Dallas, Texas, June 06, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health...
PrimaryLogo_Mango-05.png
Mangoceuticals, Inc. Announces Completion of First Batch of Mango ED Products for Marketing and Distribution in Mexico and Latin American Markets
May 28, 2024 08:30 ET | Mangoceuticals, Inc.
Dallas, Texas, May 28, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health...
PrimaryLogo_Mango-05.png
MangoRx Engages Renown International Digital and Performance Marketing Company Crakmedia to Champion its Digital Marketing Efforts
May 23, 2024 08:30 ET | Mangoceuticals, Inc.
Dallas, TX, May 23, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and...
PrimaryLogo_Mango-05.png
Mangoceuticals Subsidiary, MangoRx Mexico, Executes Technical Agreement with Mexican Pharmaceutical Manufacturer for Initial Development and Production of its Mango Erectile Dysfunction (ED) Products
April 12, 2024 08:45 ET | Mangoceuticals, Inc.
Signifies the first major step towards the application process for the certification of its Mango ED oral dissolvable products by Mexico’s health governing agency, COFEPRIS Dallas, Texas, April ...
PrimaryLogo_Mango-05.png
MangoRx Officially Launches ‘PRIME’ by MangoRx, Powered by Kyzatrex®️ FDA Approved Oral Testosterone Replacement Therapy (TRT) Treatment
March 12, 2024 09:00 ET | Mangoceuticals, Inc.
The Dallas Based, Direct-to-Consumer Telemedicine Company Brings the FDA-Approved Oral Testosterone Replacement Therapy Treatment to the Telehealth Market Dallas, Texas, March 12, 2024 (GLOBE...